OncoCyte Corp logo

OncoCyte Corp

$ 4.13 (0%) Feb 3
P/E:
At Loss
P/B:
0.60
Market Cap:
$ 46.27M
Enterprise V:
$ 17.56M
Volume:
-
Avg Vol (2M):
-
Also Trade In:
Volume:
-
Market Cap $:
46.27M
PE Ratio:
At Loss
Avg Vol (2-Month):
-
Enterprise Value $:
17.56M
PB Ratio:
0.60

Business Description

Description
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Name Current Vs Industry Vs History
Cash-To-Debt 8.63
Equity-to-Asset 0.49
Debt-to-Equity 0.05
Debt-to-EBITDA -0.06
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.68
Distress
Grey
Safe
Beneish M-Score -0.69
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.83
Quick Ratio 2.83
Cash Ratio 2.51
Days Inventory 12.68
Days Sales Outstanding 75.58
Days Payable 87.78

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -31.4
Name Current Vs Industry Vs History
Gross Margin % -8.05
Operating Margin % -707.4
Net Margin % -788.06
ROE % -82.55
ROA % -39.75
ROIC % -44.65
ROC (Joel Greenblatt) % -636.25
ROCE % -43.33

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 4.81
PB Ratio 0.6
EV-to-EBIT -0.28
EV-to-EBITDA -0.3
EV-to-Revenue 2.17
EV-to-FCF -0.37
Earnings Yield (Greenblatt) % -357.14